PROTAC Linker Optimization for CDK4/6 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PROTACs face challenges in optimizing linker length and hydrophobicity, which affects their specificity and efficacy in degrading target proteins, particularly in cancer therapy where precise protein degradation is crucial.
Innovation Solution
Development of novel compounds with specific linker groups, such as those described in the formulae provided, which optimize linker length and hydrophobicity to enhance the recruitment of E3 ligases for targeted protein degradation, including CDK4 and CDK6, using a PROTAC approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the tether length is increased to reduce steric interactions during E3 ligase recruitment, then the functional activity is improved, but the molecular weight and complexity of the PROTAC increases
Solution Approach 1:
The patent optimizes the tether length parameter to achieve the optimal balance between reducing steric interactions and maintaining molecular feasibility. Specifically, tethers with 2-6 methylene groups were found to provide optimal functionality while avoiding excessive complexity.
Solution Approach 2:
The patent introduces hydrophobic groups at specific locations within the tether structure to locally enhance E3 ligase recruitment capability. This allows the tether to have different properties at different positions - hydrophobic regions for E3 binding and hydrophilic regions for flexibility.
2Reliability
If the tether hydrophobicity is increased to enhance E3 ligase recruitment, then the binding affinity is improved, but the risk of non-specific binding and off-target effects increases
Solution Approach 1:
The patent places hydrophobic groups at specific positions within the tether rather than making the entire tether hydrophobic. This localized hydrophobicity provides sufficient E3 ligase recruitment capability while limiting the overall hydrophobic surface area that could cause non-specific binding.
Solution Approach 2:
The patent optimizes the hydrophobicity parameter by controlling the number, size, and positioning of hydrophobic groups in the tether. This allows tuning the balance between E3 recruitment affinity and specificity to minimize off-target effects.
3Reliability
If the PROTAC is designed to target specific proteins like CDK4 and CDK6, then the selectivity is improved, but the complexity of optimizing linker parameters increases
Solution Approach 1:
The patent divides the PROTAC into distinct functional segments: a target protein-binding ligand, a tether, and an E3 ligase-recruiting ligand. This segmentation allows independent optimization of each component's parameters, making the overall design more manageable while achieving high specificity for targets like CDK4 and CDK6.
Solution Approach 2:
The patent systematically varies key parameters including tether length (number of methylene groups), hydrophobicity (type and position of hydrophobic groups), and ligand structure to optimize for specific target proteins. This parameter optimization approach enables tailored PROTACs for different cancer indications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate improved selectivity and efficacy in degrading target proteins, potentially offering a more effective treatment for cancers with aberrant CDK4 or CDK6 signaling by inducing proteasome-dependent degradation, thereby inhibiting cancer cell proliferation.
Implementation Method 1
The second ligand is for recruitment of an E3 ligase that ubiquitinates the protein and targets it for proteolysis by the 26S proteasome
Implementation Method 2
targets it for proteolysis by the 26S proteasome
Data Source
AI summary
The present disclosure provides compounds of the formula (I) wherein these compounds contain a ligand which binds to one or more target proteins such as CDK4 or CDK6 and a ligand which binds to the machinery associated with the ubiquitinating protein machinery. Also provided herein are methods of using these compounds in compositions or methods of treating patients with these compounds for the treatment of a disease or disorders such as cancer.